The adverse effects of off-target mediated CAR T activation in healthy tissues could be catastrophic for patients who receive novel cell therapies. .. Read more As such, ensuring that cell therapies are specific to their intended targets is vital, particularly when assessing potential safety implications prior to clinical studies. The Human Cell Microarray technology is the only platform for specificity screening of final, whole cell therapies (such as CAR T cells), as well as profiling precursor molecules (ScFv, antibodies etc.). This allows any potential off-target liabilities to be monitored and managed throughout discovery and development, from lead selection through to safety assessment prior to regulatory submission. This webinar provides an overview of the Cell Microarray technology, with a particular focus on the specificity/off-target screening and de-risking of cell therapy programs, particularly in the CAR T sphere. Diogo is fluent in Portuguese & English and also speaks Spanish & French. Prior to Retrogenix, Diogo worked in technical sales roles for a global chromatography manufacturer and a clinical management software provider.
- Share your Experience
More Events From The Organizer
- Methods to Mitigate Target Int..02 Dec 2020Online